The Global Neurodegeneration Proteomics Consortium (GNPC) unveiled the world's largest proteomic dataset related to dementia, incorporating over 250 million unique protein measurements from more than 35,000 biofluid samples including blood plasma and cerebrospinal fluid. Accompanied by clinical data from 23 global research groups, the data elucidate disease-specific biomarker profiles and overlapping pathways across Alzheimer's, Parkinson's, frontotemporal dementia, and amyotrophic lateral sclerosis. These open-access data sets, published in Nature Medicine and Nature Aging, provide an invaluable resource for early diagnosis, therapeutic target identification, and pathogenetic insights, endorsed by notable figures such as Bill Gates.